What Is NA-931 (Bioglutide)? The Quadruple Agonist Most People Have Barely Heard Of
NA-931, also called Bioglutide, is a quadruple-agonist obesity asset combining GLP-1, GIP, glucagon, and IGF-1. It matters because it is part of the industry's attempt to see how far multi-signal biology can go beyond first-wave incretins.
Why this matters
People search this because the drug sits in a part of the pipeline that still feels undercovered relative to how ambitious the mechanism is.
Current read
NA-931 is interesting because it is not just another GLP-1 variation. The question is whether the mechanistic ambition turns into a believable efficacy and tolerability profile.
Primary query
what is na-931 bioglutide
Page type
Pipeline Theme
Lead read
NA-931 (Bioglutide)
Stage mix
1 phase 2 · 1 phase 1 · 1 phase 3
Pipeline facts for search and AI answers
What this pipeline theme page answers
Primary query
what is na-931 bioglutide
The page is built to answer this pipeline query directly before routing readers deeper.
Tracker type
Pipeline Theme
This page answers a focused pipeline question and connects it to the compounds, timelines, and comparisons that matter most.
Lead read
NA-931 (Bioglutide)
NA-931 is interesting because it is not just another GLP-1 variation. The question is whether the mechanistic ambition turns into a believable efficacy and tolerability profile.
Stage mix
1 phase 2 · 1 phase 1 · 1 phase 3
FormBlends separates early pipeline interest from late-stage, filed, and approved assets.
Direct answer
What is it?
NA-931 (Bioglutide) is a phase 2 program from Biomed Industries built around GLP-1/GIP/Glucagon/IGF-1.
Why does it matter?
NA-931, also called Bioglutide, is a quadruple-agonist obesity asset combining GLP-1, GIP, glucagon, and IGF-1. It matters because it is part of the industry's attempt to see how far multi-signal biology can go beyond first-wave incretins.
What should you read next?
What we know right now
NA-931, also called Bioglutide, is a quadruple-agonist obesity asset combining GLP-1, GIP, glucagon, and IGF-1. It matters because it is part of the industry's attempt to see how far multi-signal biology can go beyond first-wave incretins.
NA-931 is interesting because it is not just another GLP-1 variation. The question is whether the mechanistic ambition turns into a believable efficacy and tolerability profile.
Right now this page is anchored by NA-931 (Bioglutide), BI 3034701, Retatrutide, which is why the lane feels more concrete than a generic trend piece.
What is still uncertain
This topic includes at least one late-stage asset, which means the lane is more than conceptual. The open question is usually positioning, timing, and differentiation.
The next milestone is decisive late-stage readouts and filing discipline. At this stage, weak differentiation can matter as much as efficacy.
The biggest mistake in obesity pipeline content is treating strategic interest like commercial inevitability. This page is built to keep those two things separate.
What FormBlends is watching
- Whether the quadruple-mechanism framing survives closer scrutiny
- How much proof-of-concept data emerges in humans
- Whether the program starts drawing more attention against better-known triple agonists
Decision path
How should I interpret What Is NA-931 (Bioglutide)? The Quadruple Agonist Most People Have Barely Heard Of?
This pipeline page is a decision aid for market context, not a patient access page. Use it to understand which mechanisms, companies, and trial stages are worth watching before comparing anything to available care.
- Topic
- what is na-931 bioglutide
- Type
- Pipeline Theme
- Tracked names
- 3
- Stage mix
- 1 phase 2 · 1 phase 1 · 1 phase 3
Step 1
Check maturity
This topic includes at least one late-stage asset, which means the lane is more than conceptual. The open question is usually positioning, timing, and differentiation.
Step 2
Watch the next signal
The next milestone is decisive late-stage readouts and filing discipline. At this stage, weak differentiation can matter as much as efficacy.
Open status hubStep 3
Compare to care today
Pipeline excitement should be separated from treatment decisions that require provider review, a legally available medication, and follow-up.
View current optionsHow this lane stacks up right now
A quick read on the compounds carrying the most weight on this page.
| Compound | Developer | Mechanism | Stage | Next step |
|---|---|---|---|---|
| NA-931 (Bioglutide) | Biomed Industries | GLP-1/GIP/Glucagon/IGF-1 | Phase 2 | Read status page |
| BI 3034701 | Boehringer/Gubra | Triple agonist | Phase 1 | Read status page |
| Retatrutide | Eli Lilly | GLP-1/GIP/Glucagon | Phase 3 | Read status page |
Featured compounds in this lane
These are the names currently doing the real work in this part of the pipeline.
Quadruple agonists
NA-931 (Bioglutide)
Biomed Industries · Phase 2
GLP-1/GIP/Glucagon/IGF-1
Related comparisons
BI 3034701 vs NA-931: Early Triple Agonist vs Quadruple Ambition
BI 3034701 is the more disciplined early-development story. NA-931 is the more ambitious one. If you think obesity winners will still come from relatively controlled multi-agonist engineering, BI 3034701 is easier to underwrite. If you think the field keeps rewarding bigger mechanism swings, NA-931 is the bolder watch.
BI 3034701 vs Mazdutide: Early Triple-Agnostic Hope vs Nearer GLP-1/Glucagon Reality
Mazdutide is the more tangible asset today. BI 3034701 is still a development-stage option on what might matter later. This is mostly a comparison between current relevance and future possibility.
Novo Triple vs Kailera Triple: Sponsored Early Triple Agonist vs Preclinical Challenger
Novo's triple program is the more credible asset today because it has sponsor weight and human-development momentum. Kailera's program is mainly a high-risk watchlist entry until it crosses into stronger human data territory.
FormBlends separates trial-stage tracking from actual patient availability.
Late-stage, filed, and approved assets are treated differently from early exploratory programs.
This page is meant to answer the query fast, then route readers into compound, status, and comparison pages for deeper analysis.